Loading...
OTCM
PBBIF
Market cap409mUSD
Nov 20, Last price  
31.60
Name

Probi AB

Chart & Performance

D1W1MN
OTCM:PBBIF chart
P/E
—
P/S
—
EPS
1.48
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
0.77%
Revenues
628m
+1.52%
63,612,00054,902,00037,215,00043,568,00067,959,00065,466,00080,381,00094,379,000100,392,000103,554,000137,752,000215,981,000443,695,000612,244,000604,117,000626,192,000717,165,000658,180,000618,285,000627,687,000
Net income
17m
-58.60%
7,366,0008,833,000-4,834,00024,528,0007,995,00010,751,00013,661,00014,193,00013,505,00015,045,00021,765,00049,039,000108,567,00069,092,00076,250,00085,887,00092,693,00083,145,00040,622,00016,819,000
CFO
86m
-45.19%
04,924,000-3,058,00017,803,00013,113,00017,654,00028,708,00014,856,00024,201,00024,696,00037,233,00062,086,00086,349,000145,688,000127,866,000173,611,000143,364,000154,195,000156,094,00085,551,000
Dividend
May 08, 20240.11869 /sh
Earnings
Jul 14, 2025

Profile

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
URL
https://probi.com/
IPO date
Jan 01, 1998
Employees
164
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
627,687
1.52%
618,285
-6.06%
Cost of revenue
616,407
568,033
Unusual Expense (Income)
NOPBT
11,280
50,252
NOPBT Margin
1.80%
8.13%
Operating Taxes
563
11,352
Tax Rate
4.99%
22.59%
NOPAT
10,717
38,900
Net income
16,819
-58.60%
40,622
-51.14%
Dividends
(14,812)
(14,812)
Dividend yield
0.64%
0.64%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
15,585
16,667
Long-term debt
92,009
123,869
Deferred revenue
Other long-term liabilities
5,272
5,480
Net debt
(295,100)
(263,680)
Cash flow
Cash from operating activities
85,551
156,094
CAPEX
(33,163)
(64,609)
Cash from investing activities
(54,171)
(64,589)
Cash from financing activities
(23,957)
(29,308)
FCF
26,519
(1,991)
Balance
Cash
329,650
323,706
Long term investments
73,044
80,510
Excess cash
371,310
373,302
Stockholders' equity
671,459
810,362
Invested Capital
1,056,839
1,112,899
ROIC
0.99%
3.64%
ROCE
0.79%
3.35%
EV
Common stock shares outstanding
11,394
11,394
Price
203.00
-0.49%
204.00
-48.68%
Market cap
2,313,007
-0.49%
2,324,402
-48.68%
EV
2,017,907
2,060,722
EBITDA
107,483
135,934
EV/EBITDA
18.77
15.16
Interest
2,027
2,419
Interest/NOPBT
17.97%
4.81%